Stock Analysis

ASX Penny Stocks: Prescient Therapeutics Among 3 Noteworthy Picks

Published

The Australian stock market is showing resilience, with the ASX200 rising by 0.80% and sectors like Materials and Real Estate leading the charge after recent volatility. In such a dynamic market landscape, investors often look for stocks that offer both value and growth potential, which can sometimes be found in smaller or newer companies. Though the term "penny stocks" might seem outdated, these investments can still provide significant opportunities when backed by solid financials; we'll explore three noteworthy examples that stand out for their financial strength and potential.

Top 10 Penny Stocks In Australia

NameShare PriceMarket CapFinancial Health Rating
Embark Early Education (ASX:EVO)A$0.76A$139.45M★★★★☆☆
LaserBond (ASX:LBL)A$0.60A$70.33M★★★★★★
Helloworld Travel (ASX:HLO)A$1.85A$301.21M★★★★★★
Austin Engineering (ASX:ANG)A$0.555A$344.18M★★★★★☆
MaxiPARTS (ASX:MXI)A$1.82A$100.68M★★★★★★
Navigator Global Investments (ASX:NGI)A$1.66A$813.53M★★★★★☆
Perenti (ASX:PRN)A$1.195A$1.1B★★★★★★
Atlas Pearls (ASX:ATP)A$0.135A$58.82M★★★★★★
Joyce (ASX:JYC)A$4.49A$132.44M★★★★★★
Big River Industries (ASX:BRI)A$1.32A$112.68M★★★★★☆

Click here to see the full list of 1,037 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Prescient Therapeutics (ASX:PTX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing cancer treatments in Australia, with a market cap of A$34.63 million.

Operations: The company generates revenue from its Clinical Stage Oncology segment, amounting to A$3.71 million.

Market Cap: A$34.63M

Prescient Therapeutics, a clinical-stage oncology company in Australia with a market cap of A$34.63 million, is currently pre-revenue and unprofitable, reporting a net loss of A$8.24 million for the year ended June 30, 2024. The company has experienced management and board members with average tenures over nine years each. Despite its financial challenges, Prescient maintains a strong cash position with short-term assets significantly exceeding liabilities and sufficient runway for over a year based on current cash flow trends. Recent executive changes include the planned departure of CEO Steven Yatomi-Clarke by February 2025.

ASX:PTX Financial Position Analysis as at Nov 2024
ASX:PTX Financial Position Analysis as at Nov 2024

Quickstep Holdings (ASX:QHL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Quickstep Holdings Limited manufactures and sells advanced composites for the defense, commercial aerospace, automotive, and other industries in Australia, the United Kingdom, and the United States with a market cap of A$27.26 million.

Operations: The company generates revenue from its Quickstep Structures segment, which amounted to A$88.97 million.

Market Cap: A$27.26M

Quickstep Holdings, with a market cap of A$27.26 million, faces financial challenges as it remains unprofitable despite generating A$88.97 million in revenue from its Quickstep Structures segment. The company's net debt to equity ratio is high at 53.2%, though short-term assets exceed both short and long-term liabilities, providing some financial stability. Recent executive changes include the departure of CEO Mark Burgess and CFO Dexter Clarke, with Demi Stefanova stepping in as interim CEO and Martyn Dominy as interim CFO. Additionally, ASDAM Operations Pty Ltd proposed acquiring Quickstep for A$28.7 million on November 6, 2024.

ASX:QHL Debt to Equity History and Analysis as at Nov 2024
ASX:QHL Debt to Equity History and Analysis as at Nov 2024

Viking Mines (ASX:VKA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Viking Mines Limited is a mineral exploration company based in Australia with a market cap of A$12.75 million.

Operations: The company generates revenue from its Resources Sector, amounting to A$0.15 million.

Market Cap: A$12.75M

Viking Mines, with a market cap of A$12.75 million, is pre-revenue and currently unprofitable, reporting a net loss of A$2.77 million for the year ended June 30, 2024. Despite this, the company maintains financial resilience with no debt and sufficient cash runway exceeding three years due to positive free cash flow growth. However, shareholders have faced dilution over the past year as shares outstanding increased by 3.6%. The company's short-term assets comfortably cover both its short- and long-term liabilities, but its share price has been highly volatile recently.

ASX:VKA Revenue & Expenses Breakdown as at Nov 2024
ASX:VKA Revenue & Expenses Breakdown as at Nov 2024

Make It Happen

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com